Skip to main content
Erschienen in: International Urology and Nephrology 8/2016

11.05.2016 | Nephrology - Translational Section

Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience

verfasst von: Hong-Feng Huang, Jing-Yi Zhou, Wen-Qing Xie, Jian-Yong Wu, Hao Deng, Jiang-Hua Chen

Erschienen in: International Urology and Nephrology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the long-term effects of the interleukin-2 receptor antagonist basiliximab versus rabbit antithymocyte globulin as an induction therapy for living-related renal transplantation.

Methods

This is a prospective, open-label, nonrandomized, controlled study including 213 cases of renal transplant. Immunosuppressive therapy containing calcineurin inhibitors, mycophenolate mofetil and steroids was applied in all cases. The interleukin-2 receptor antagonist group (IL2Ra group) included 108 cases with 20 mg basiliximab induction on Day 0 and Day 4. The other 105 cases comprised the rabbit antithymocyte globulin group (rATG group) with 1.0 mg/kg/day ATG induction from Day 0 to Day 4. The primary endpoint was biopsy-proven acute rejection. Other endpoints included delayed graft function (DGF), graft loss and death.

Results

All patients were followed up for 3 years. Acute rejection rates in the IL2Ra group and the ATG group were 5.6 and 3.8 % (P = 0.781), and the differences in the DGF rates, graft loss and death were insignificant between groups. All-cause infection rates in the IL2Ra and rATG groups were 26.9 and 43.8 % (P = 0.010). Urinary tract infections were more common in the rATG group than in the IL2Ra group (15.2 vs 6.5 %, P = 0.040). Specific viral infection rates were significantly different (18.1 % in rATG group vs 8.3 % in IL2Ra group, P = 0.035).

Conclusions

IL2Ra and rATG had no significant differences as induction therapies during the perioperative period of living-related renal transplantation, according to acute rejection rates, DGF rates, graft loss, 1- and 3-year patient/graft survival rates. However, the incidence of infection, especially of urinary tract infection and specific viral infection, was higher in rATG-induced patients.
Literatur
1.
Zurück zum Zitat Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D (2006) Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355(19):1967–1977CrossRefPubMed Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D (2006) Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355(19):1967–1977CrossRefPubMed
2.
Zurück zum Zitat Bonnefoy-Berard N, Revillard JP (1996) Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transpl 15(5):435–442 Bonnefoy-Berard N, Revillard JP (1996) Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transpl 15(5):435–442
3.
Zurück zum Zitat Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP (2003) Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 75(5):657–662CrossRefPubMed Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP (2003) Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 75(5):657–662CrossRefPubMed
4.
Zurück zum Zitat Woodside KJ, Hu M, Meng T, Hunter GC, Sower LE, Daller JA (2003) Differential effects of interleukin-2 blockade on apoptosis in naive and activated human lymphocytes. Transplantation 75(10):1631–1635CrossRefPubMed Woodside KJ, Hu M, Meng T, Hunter GC, Sower LE, Daller JA (2003) Differential effects of interleukin-2 blockade on apoptosis in naive and activated human lymphocytes. Transplantation 75(10):1631–1635CrossRefPubMed
5.
Zurück zum Zitat Amlot PL, Rawlings E, Fernando ON et al (1995) Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 60(7):748–756CrossRefPubMed Amlot PL, Rawlings E, Fernando ON et al (1995) Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 60(7):748–756CrossRefPubMed
6.
Zurück zum Zitat Bourdage JS, Hamlin DM (1995) Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 59(8):1194–1200CrossRefPubMed Bourdage JS, Hamlin DM (1995) Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 59(8):1194–1200CrossRefPubMed
7.
Zurück zum Zitat Zand MS, Vo T, Huggins J et al (2005) Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79(11):1507–1515CrossRefPubMed Zand MS, Vo T, Huggins J et al (2005) Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79(11):1507–1515CrossRefPubMed
8.
Zurück zum Zitat Liu Y, Zhou P, Han M, Xue CB, Hu XP, Li C (2010) Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. Transpl Proc 42(5):1667–1670CrossRef Liu Y, Zhou P, Han M, Xue CB, Hu XP, Li C (2010) Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. Transpl Proc 42(5):1667–1670CrossRef
9.
Zurück zum Zitat AI Najjar A, Etienne I, Le Pogamp P et al (2006) Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transpl Proc 38(7):2298–2299CrossRef AI Najjar A, Etienne I, Le Pogamp P et al (2006) Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transpl Proc 38(7):2298–2299CrossRef
10.
Zurück zum Zitat Patel HV, Kute VB, Vanikar AV et al (2014) Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation. Saudi J Kidney Dis Transpl 25(4):819–822CrossRefPubMed Patel HV, Kute VB, Vanikar AV et al (2014) Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation. Saudi J Kidney Dis Transpl 25(4):819–822CrossRefPubMed
11.
Zurück zum Zitat Pilch NA, Taber DJ, Moussa O et al (2014) Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg 259(5):888–893CrossRefPubMed Pilch NA, Taber DJ, Moussa O et al (2014) Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg 259(5):888–893CrossRefPubMed
12.
Zurück zum Zitat Brokhof MM, Sollinger HW, Hager DR et al (2014) Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation 97(6):612–617CrossRefPubMedPubMedCentral Brokhof MM, Sollinger HW, Hager DR et al (2014) Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation 97(6):612–617CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Wang W, Yin H, Li XB et al (2012) A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin. Chin Med J (Engl) 125(6):1135–1140 Wang W, Yin H, Li XB et al (2012) A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin. Chin Med J (Engl) 125(6):1135–1140
14.
Zurück zum Zitat Taber DJ, Weimert NA, Henderson F et al (2008) Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation. Transpl Proc 40(10):3401–3407CrossRef Taber DJ, Weimert NA, Henderson F et al (2008) Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation. Transpl Proc 40(10):3401–3407CrossRef
15.
Zurück zum Zitat Kim JM, Jang HR, Kwon CH et al (2012) Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study. Transpl Proc 44(1):167–170CrossRef Kim JM, Jang HR, Kwon CH et al (2012) Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study. Transpl Proc 44(1):167–170CrossRef
16.
Zurück zum Zitat Buhaescu I, Segall L, Goldsmith D, Covic A (2005) New immunosuppressive therapies in renal transplantation: monoclonal antibodies. J Nephrol 18(5):529–536PubMed Buhaescu I, Segall L, Goldsmith D, Covic A (2005) New immunosuppressive therapies in renal transplantation: monoclonal antibodies. J Nephrol 18(5):529–536PubMed
17.
Zurück zum Zitat Cai J, Terasaki PI (2010) Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 90(12):1511–1515CrossRefPubMed Cai J, Terasaki PI (2010) Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 90(12):1511–1515CrossRefPubMed
18.
Zurück zum Zitat Sandrini S (2005) Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin Transpl 19(6):705–710CrossRef Sandrini S (2005) Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin Transpl 19(6):705–710CrossRef
19.
Zurück zum Zitat Mourad G, Morelon E, Noel C, Glotz D, Lebranchu Y (2012) The role of thymoglobulin induction in kidney transplantation: an update. Clin Transpl 26(5):E450–464CrossRef Mourad G, Morelon E, Noel C, Glotz D, Lebranchu Y (2012) The role of thymoglobulin induction in kidney transplantation: an update. Clin Transpl 26(5):E450–464CrossRef
20.
Zurück zum Zitat Tullius SG, Pratschke J, Strobelt V et al (2003) ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transpl Proc 35(6):2100–2101CrossRef Tullius SG, Pratschke J, Strobelt V et al (2003) ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transpl Proc 35(6):2100–2101CrossRef
21.
Zurück zum Zitat Gabardi S, Martin ST, Roberts KL, Grafals M (2011) Induction immunosuppressive therapies in renal transplantation. Am J Health Syst Pharm 68(3):211–218CrossRefPubMed Gabardi S, Martin ST, Roberts KL, Grafals M (2011) Induction immunosuppressive therapies in renal transplantation. Am J Health Syst Pharm 68(3):211–218CrossRefPubMed
22.
Zurück zum Zitat van den Hoogen MW, Hoitsma AJ, Hilbrands LB (2012) Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation. Expert Opin Biol Ther 12(8):1031–1042CrossRefPubMed van den Hoogen MW, Hoitsma AJ, Hilbrands LB (2012) Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation. Expert Opin Biol Ther 12(8):1031–1042CrossRefPubMed
23.
Zurück zum Zitat Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D (2004) Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78(4):584–590CrossRefPubMed Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D (2004) Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78(4):584–590CrossRefPubMed
24.
Zurück zum Zitat Lebranchu Y, Bridoux F, Buchler M et al (2002) Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transpl 2(1):48–56CrossRef Lebranchu Y, Bridoux F, Buchler M et al (2002) Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transpl 2(1):48–56CrossRef
25.
Zurück zum Zitat Sollinger H, Kaplan B, Pescovitz MD et al (2001) Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 72(12):1915–1919CrossRefPubMed Sollinger H, Kaplan B, Pescovitz MD et al (2001) Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 72(12):1915–1919CrossRefPubMed
26.
Zurück zum Zitat Kyllonen LE, Eklund BH, Pesonen EJ, Salmela KT (2007) Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation 84(1):75–82CrossRefPubMed Kyllonen LE, Eklund BH, Pesonen EJ, Salmela KT (2007) Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation 84(1):75–82CrossRefPubMed
Metadaten
Titel
Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience
verfasst von
Hong-Feng Huang
Jing-Yi Zhou
Wen-Qing Xie
Jian-Yong Wu
Hao Deng
Jiang-Hua Chen
Publikationsdatum
11.05.2016
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 8/2016
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-016-1307-y

Weitere Artikel der Ausgabe 8/2016

International Urology and Nephrology 8/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.